



Prescription Fax Order Form

PHILRx Pharmacy

Fax this completed Prescription Form to PHILRx: 888-975-0603

Patient Information

Name: _____ Date of Birth (MM/DD/YYYY): _____

Cell Phone: (____) _____ Email: _____

Shipping Address: _____ City: _____ State: _____ Zip: _____

Sex: Male Female Primary Language: _____

Allergies: _____

Prescriber Information

Name: _____ NPI #: _____

Address: _____ City: _____ State: _____ Zip: _____

Office Contact Name: _____

Phone: (____) _____ Fax: (____) _____ (for prescription status updates)

Provider Signature: _____ Date: _____

Name of person sending the fax IF NOT THE PRESCRIBER: _____

YUVEZZI Prescription Information

Strength/Form	How Supplied	Dosing/Administration Instructions	Refills
Carbachol 2.75% (27.5 mg/mL) and brimonidine tartrate 0.1% (1 mg/mL)	Carton box of 30 single-dose vials (6 pouches each with 5 single-dose vials)	One drop in each eye once daily. One single-dose vial may be used to dose both eyes. Discard vial and any remaining contents immediately after use.	<input type="checkbox"/> 30-day supply <input type="checkbox"/> 90-day supply

Please see Indication and Important Safety Information on following page and full Prescribing Information at YUVEZZIlecp.com



© 2026 Tenpoint Therapeutics, Ltd. ALL RIGHTS RESERVED
YUVEZZI is a trademark of Visus Therapeutics, Inc. TENPOINT is a trademark of Tenpoint Therapeutics Holding Limited.
Any other brand names are trademarks of the respective owners.
Visus Therapeutics, Inc., an affiliate of Tenpoint Therapeutics, Ltd., Seattle, Washington, 98109, USA.
MAT-US-YZ-0140 03/26



Prescription Fax Order Form

PHILRx Pharmacy

Indication

YUVEZZI is indicated for the treatment of presbyopia in adults.

Important Safety Information

Contraindications

YUVEZZI is contraindicated in patients with known hypersensitivity to the active ingredients or to any of the excipients.

Warnings and Precautions

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics. Advise patients to exercise caution in night driving and other hazardous activities in poor illumination.

Rare cases of retinal tear and detachment have been reported with miotics. Individuals with pre-existing retinal disease are at increased risk. Examination of the retina is advised in all patients prior to the initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

YUVEZZI is not recommended to be used when iritis is present.

Avoid touching the vial to the eye, eyelids, or to any other surface.

YUVEZZI may potentiate syndromes associated with vascular insufficiency.

Drug Interactions

- Antihypertensives/cardiac glycosides, tricyclic antidepressants, and monoamine oxidase inhibitors: caution advised.
- CNS depressants: consider the possibility of additive or potentiating effects.

Adverse Reactions

The most common adverse reactions were eye pain upon instillation, visual impairment, eye irritation upon instillation, and headache. The majority of adverse events were mild, transient, and self-resolving.

To report SUSPECTED ADVERSE REACTIONS, contact Visus Therapeutics, Inc., at 1-888-735-0821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information at YUVEZZIecp.com

